NDAORALTABLETPriority Review
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
28
Data completeness
7/8 — Comprehensive
Priority Review
LORBRENA (lorlatinib) by Pfizer is kinase inhibitors [moa]. Approved for non-small cell lung cancer, alk-positive non-small cell lung cancer. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LORBRENA (lorlatinib) is an oral small-molecule kinase inhibitor approved by the FDA on November 2, 2018, and currently in peak commercial lifecycle stage. It is a second-generation ALK inhibitor designed to overcome resistance mutations in ALK-positive non-small cell lung cancer. The drug represents an important treatment option for patients who have progressed on first-generation ALK inhibitors, offering improved CNS penetration and broader kinase selectivity.
$0.1BPart D
12.4 years to LOEMechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Worked on LORBRENA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.